백신 시장 예측(-2034년) : 백신 유형, 가수, 대상 질환, 투여 경로, 연령층, 제조 모델, 보관·물류, 최종사용자, 유통 채널 및 지역별 세계 분석

According to Stratistics MRC, the Global Vaccine Market is accounted for $91.4 billion in 2026 and is expected to reach $155.9 billion by 2034 growing at a CAGR of 6.9% during the forecast period. Vaccines are biological preparations that provide active acquired immunity to specific infectious diseases, playing a critical role in global public health through disease prevention and eradication efforts. The market encompasses a wide range of vaccine types including pediatric, adult, influenza, COVID-19, travel, and therapeutic vaccines targeting various infectious conditions. Increasing disease outbreaks, growing geriatric populations susceptible to infections, continuous research investments, and expanding immunization programs across developing nations collectively drive the sustained expansion of this essential healthcare market.

Market Dynamics:

Driver:

Rising incidence of infectious diseases and pandemic threats

Recurring outbreaks of infectious diseases including measles, dengue, Ebola, and novel influenza strains continuously reinforce the critical importance of vaccination programs worldwide. The recent COVID-19 pandemic demonstrated both the devastating economic and health impacts of emerging pathogens and the remarkable potential of rapid vaccine development platforms. This heightened awareness has translated into sustained government funding, accelerated regulatory pathways, and unprecedented public acceptance of immunization. Emerging economies facing dual burdens of endemic and emerging infectious diseases represent particularly strong demand drivers, as healthcare infrastructure expansion increasingly prioritizes preventative medicine over reactive treatment approaches.

Restraint:

High costs of vaccine development and cold chain logistics

Developing a single new vaccine typically requires ten to fifteen years and investments exceeding one billion dollars, creating substantial barriers for smaller manufacturers and emerging market entrants. The stringent regulatory environment demands extensive clinical trials across diverse populations, further escalating development timelines and financial requirements. Additionally, the temperature-sensitive nature of most vaccines necessitates sophisticated cold chain infrastructure from manufacturing facilities to final administration points, representing significant logistical challenges in remote and resource-limited settings. These combined cost pressures limit market accessibility, particularly for vaccines targeting diseases prevalent primarily in low-income regions with limited ability to pay premium pricing.

Opportunity:

Expansion of mRNA and novel platform technologies

The remarkable success of mRNA vaccines during the COVID-19 pandemic has revolutionized vaccine development paradigms, opening unprecedented opportunities for rapid response to emerging threats and previously challenging targets. These platform technologies enable faster design and manufacturing adaptation compared to traditional approaches, substantially reducing development timelines for pandemic responses. Beyond infectious diseases, mRNA platforms are being investigated for therapeutic cancer vaccines, autoimmune conditions, and rare genetic disorders, dramatically expanding the addressable market. Multiple manufacturers are now investing heavily in platform diversification, manufacturing scale-up, and distribution capabilities, positioning these technologies as transformative forces across the broader vaccine landscape.

Threat:

Vaccine hesitancy and misinformation campaigns

Persistent public skepticism regarding vaccine safety and efficacy continues to undermine immunization coverage rates even in well-developed healthcare systems with established track records of disease prevention. Social media platforms and online communities amplify scientifically unsubstantiated claims, creating information ecosystems where misinformation spreads faster than accurate public health messaging. This hesitancy has contributed to resurgent measles outbreaks in regions previously declared elimination-free and slowed COVID-19 booster adoption despite ongoing viral evolution. Addressing these behavioral barriers requires substantial investments in community engagement, healthcare worker training, and culturally tailored communication strategies, representing non-technical challenges that traditional pharmaceutical approaches cannot alone resolve.

Covid-19 Impact:

The COVID-19 pandemic fundamentally transformed the vaccine market through unprecedented collaboration, funding acceleration, and public awareness. Regulatory bodies implemented emergency use authorizations and rolling review processes, compressing traditional multi-year approval timelines into months without compromising safety standards. Massive government investments in manufacturing capacity, including partnerships between competing pharmaceutical companies, enabled billions of doses to be produced and distributed globally. The pandemic also normalized adult vaccination as a routine public health practice in many regions, creating sustained demand for booster doses and expanded adult immunization schedules. These structural changes have permanently elevated baseline vaccine utilization and accelerated pipeline development across multiple disease targets.

The Hospitals segment is expected to be the largest during the forecast period

The Hospitals segment is expected to account for the largest market share during the forecast period, driven by their comprehensive infrastructure, trained medical personnel, and ability to handle complex vaccination scenarios including adverse reaction management. Hospitals serve as primary vaccination sites for newborns, pre-travel consultations, occupational health programs, and catch-up immunizations for previously missed doses. Their centralized role in healthcare delivery systems, particularly in managing large-scale emergency responses, makes them indispensable partners in routine and pandemic immunization efforts. The integration of vaccination records with electronic health records in hospital settings further strengthens this channel's dominance by enabling better tracking, reminder systems, and coordination across multiple vaccine types and schedules.

The Retail Pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Retail Pharmacies segment is predicted to witness the highest growth rate, reflecting the shift toward convenient, accessible vaccination services outside traditional medical settings. Pharmacies offer extended hours, walk-in appointments, and locations embedded within communities, significantly reducing access barriers for working adults and rural populations. Expanded scope-of-practice regulations across multiple countries now authorize pharmacists to administer a growing range of vaccines, including influenza, pneumococcal, shingles, and COVID-19 boosters. The retail pharmacy model's lower overhead costs compared to hospital settings enable more competitive pricing, while established medication management systems integrate seamlessly with immunization services, creating efficient, patient-centered delivery platforms that continue gaining regulatory approval and consumer acceptance.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare infrastructure, high per capita healthcare spending, and established immunization schedules across all age groups. The region's concentration of major vaccine manufacturers and research institutions drives continuous innovation and maintains robust supply chains for routine and pandemic vaccines. Strong public-private partnerships, including extensive pharmacy-based administration networks, create multiple access points ensuring high coverage rates. Government-funded programs like Vaccines for Children eliminate cost barriers for vulnerable populations, while private insurance mandates ensure comprehensive adult coverage. This mature ecosystem, combined with ongoing investments in next-generation vaccine development, reinforces North America's market leadership throughout the forecast timeline.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by large and growing populations, expanding government immunization commitments, and improving healthcare infrastructure across multiple countries. Rapid economic growth in China, India, and Southeast Asian nations has enabled increased domestic vaccine manufacturing capacity and public health investments. Significant birth cohorts create sustained demand for pediatric vaccines, while aging populations require expanded adult immunization programs against influenza, pneumococcal disease, and herpes zoster. Regional initiatives promoting indigenous vaccine production, including the Serum Institute of India's massive manufacturing scale, reduce import dependence and improve supply security. International organization partnerships supporting immunization expansion in lower-income Asia Pacific countries further accelerate regional market growth.

Key players in the market

Some of the key players in Vaccine Market include Pfizer Inc, Moderna Inc, Johnson and Johnson, GlaxoSmithKline plc, Sanofi SA, Merck and Co Inc, AstraZeneca plc, Bharat Biotech International Limited, Serum Institute of India Pvt Ltd, Sinovac Biotech Ltd, Sinopharm Group Co Ltd, CSL Limited, Novavax Inc, BioNTech SE, Takeda Pharmaceutical Company Limited, and Emergent BioSolutions Inc.

Key Developments:

In April 2026, The European Commission approved ENFLONSIA (clesrovimab) for the prevention of RSV lower respiratory tract disease in infants during their first RSV season.

In March 2026, GSK's Respiratory Syncytial Virus (RSV) vaccine, Arexvy, received FDA approval for an expanded age indication; covering adults aged 18-49 who are at increased risk of severe infection.

In December 2025, CSL officially opened its new $1 billion world-class vaccine and antivenom manufacturing facility in Melbourne, Australia, significantly boosting onshore cell-based influenza vaccine production.

Vaccine Types Covered:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines

Valency Types Covered:

• Monovalent Vaccines
• Multivalent Vaccines

Disease Indications Covered:

• Viral Diseases
• Bacterial Diseases
• Cancer Vaccines
• Allergy Vaccines
• Other Therapeutic Vaccines

Route of Administrations Covered:

• Parenteral
• Oral
• Intranasal

Age Groups Covered:

• Pediatric Vaccines
• Adult Vaccines

Manufacturing Models Covered:

• In-House Manufacturing
• Contract Manufacturing Organizations (CMOs)
• Public Sector Manufacturing

Storage & Logistics Covered:

• Standard Cold Chain Vaccines
• Ultra-Cold Chain Vaccines
• Thermostable Vaccines

End Users Covered:

• Hospitals
• Clinics
• Vaccination Centers
• Government Immunization Programs
• NGOs & International Organizations

Distribution Channels Covered:

• Government Supply Programs
• Institutional Supply
• Retail Pharmacies
• Other Channels

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Vaccine Market, By Vaccine Type

• 5.1 Live Attenuated Vaccines
• 5.2 Inactivated Vaccines
• 5.3 Subunit Vaccines
  • 5.3.1 Recombinant Vaccines
  • 5.3.2 Conjugate Vaccines
• 5.4 Toxoid Vaccines
• 5.5 mRNA Vaccines
• 5.6 Viral Vector Vaccines
• 5.7 DNA Vaccines
• 5.8 Combination Vaccines

6 Global Vaccine Market, By Valency Type

• 6.1 Monovalent Vaccines
• 6.2 Multivalent Vaccines

7 Global Vaccine Market, By Disease Indication

• 7.1 Viral Diseases
  • 7.1.1 Influenza
  • 7.1.2 COVID-19
  • 7.1.3 Hepatitis
  • 7.1.4 HPV
  • 7.1.5 Measles, Mumps, Rubella (MMR)
  • 7.1.6 Rotavirus
  • 7.1.7 Varicella
  • 7.1.8 Respiratory Syncytial Virus (RSV)
  • 7.1.9 Other Viral Diseases
• 7.2 Bacterial Diseases
  • 7.2.1 Pneumococcal Diseases
  • 7.2.2 Meningococcal Diseases
  • 7.2.3 DTP (Diphtheria, Tetanus, Pertussis)
  • 7.2.4 Tuberculosis (BCG)
  • 7.2.5 Other Bacterial Diseases
• 7.3 Cancer Vaccines
• 7.4 Allergy Vaccines
• 7.5 Other Therapeutic Vaccines

8 Global Vaccine Market, By Route of Administration

• 8.1 Parenteral
• 8.2 Oral
• 8.3 Intranasal

9 Global Vaccine Market, By Age Group

• 9.1 Pediatric Vaccines
• 9.2 Adult Vaccines

10 Global Vaccine Market, By Manufacturing Model

• 10.1 In-House Manufacturing
• 10.2 Contract Manufacturing Organizations (CMOs)
• 10.3 Public Sector Manufacturing

11 Global Vaccine Market, By Storage & Logistics

• 11.1 Standard Cold Chain Vaccines
• 11.2 Ultra-Cold Chain Vaccines
• 11.3 Thermostable Vaccines

12 Global Vaccine Market, By End User

• 12.1 Hospitals
• 12.2 Clinics
• 12.3 Vaccination Centers
• 12.4 Government Immunization Programs
• 12.5 NGOs & International Organizations

13 Global Vaccine Market, By Distribution Channel

• 13.1 Government Supply Programs
• 13.2 Institutional Supply
• 13.3 Retail Pharmacies
• 13.4 Other Channels

14 Global Vaccine Market, By Geography

• 14.1 North America
  • 14.1.1 United States
  • 14.1.2 Canada
  • 14.1.3 Mexico
• 14.2 Europe
  • 14.2.1 United Kingdom
  • 14.2.2 Germany
  • 14.2.3 France
  • 14.2.4 Italy
  • 14.2.5 Spain
  • 14.2.6 Netherlands
  • 14.2.7 Belgium
  • 14.2.8 Sweden
  • 14.2.9 Switzerland
  • 14.2.10 Poland
  • 14.2.11 Rest of Europe
• 14.3 Asia Pacific
  • 14.3.1 China
  • 14.3.2 Japan
  • 14.3.3 India
  • 14.3.4 South Korea
  • 14.3.5 Australia
  • 14.3.6 Indonesia
  • 14.3.7 Thailand
  • 14.3.8 Malaysia
  • 14.3.9 Singapore
  • 14.3.10 Vietnam
  • 14.3.11 Rest of Asia Pacific
• 14.4 South America
  • 14.4.1 Brazil
  • 14.4.2 Argentina
  • 14.4.3 Colombia
  • 14.4.4 Chile
  • 14.4.5 Peru
  • 14.4.6 Rest of South America
• 14.5 Rest of the World (RoW)
  • 14.5.1 Middle East
    • 14.5.1.1 Saudi Arabia
    • 14.5.1.2 United Arab Emirates
    • 14.5.1.3 Qatar
    • 14.5.1.4 Israel
    • 14.5.1.5 Rest of Middle East
  • 14.5.2 Africa
    • 14.5.2.1 South Africa
    • 14.5.2.2 Egypt
    • 14.5.2.3 Morocco
    • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

• 15.1 Industry Value Network and Supply Chain Assessment
• 15.2 White-Space and Opportunity Mapping
• 15.3 Product Evolution and Market Life Cycle Analysis
• 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

• 16.1 Mergers and Acquisitions
• 16.2 Partnerships, Alliances, and Joint Ventures
• 16.3 New Product Launches and Certifications
• 16.4 Capacity Expansion and Investments
• 16.5 Other Strategic Initiatives

17 Company Profiles

• 17.1 Pfizer Inc
• 17.2 Moderna Inc
• 17.3 Johnson and Johnson
• 17.4 GlaxoSmithKline plc
• 17.5 Sanofi SA
• 17.6 Merck and Co Inc
• 17.7 AstraZeneca plc
• 17.8 Bharat Biotech International Limited
• 17.9 Serum Institute of India Pvt Ltd
• 17.10 Sinovac Biotech Ltd
• 17.11 Sinopharm Group Co Ltd
• 17.12 CSL Limited
• 17.13 Novavax Inc
• 17.14 BioNTech SE
• 17.15 Takeda Pharmaceutical Company Limited
• 17.16 Emergent BioSolutions Inc